Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.1K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.1K
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.2K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.1K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.1K
Drug Discovery: Overview01:26

Drug Discovery: Overview

12.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.5K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

1.9K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.9K
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

2.0K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genome-wide loss-of-function genetic screening identifies opioid receptor μ1 as a key regulator of L-asparaginase resistance in pediatric acute lymphoblastic leukemia.

Oncogene·2017
Same author

Cancer upregulated gene 2, a novel oncogene, confers resistance to oncolytic vesicular stomatitis virus through STAT1-OASL2 signaling.

Cancer gene therapy·2013
Same author

Targeting epigenetics through histone deacetylase inhibitors in acute lymphoblastic leukemia.

Current cancer drug targets·2011
Same author

Attenuated reovirus displays oncolysis with reduced host toxicity.

British journal of cancer·2010
Same author

Meigs's Syndrome.

British medical journal·2010
Same author

The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status.

Oncogene·2010

Related Experiment Videos

Enzastaurin: A lesson in drug development.

T Bourhill1, A Narendran1, R N Johnston1

  • 1Department of Biochemistry & Molecular Biology, Faculty of Medicine, University of Calgary, Calgary, Canada.

Critical Reviews in Oncology/Hematology
|March 23, 2017
PubMed
Summary

Enzastaurin, a protein kinase Cβ inhibitor, showed promise in preclinical cancer studies but failed in clinical trials due to poor efficacy translation and development challenges. This review examines its journey, highlighting issues in drug development and anticancer therapeutics.

Keywords:
Drug developmentEnzastaurinProtein kinase C

Related Experiment Videos

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Development

Background:

  • Enzastaurin is an orally administered drug targeting protein kinase Cβ (PKCβ), implicated in cancer signaling pathways like AKT and MAPK.
  • Preclinical studies indicated potential in preventing angiogenesis, inhibiting proliferation, and inducing apoptosis, with limited cytotoxicity in early trials.

Purpose of the Study:

  • To review the development of enzastaurin from initial drug design through clinical testing.
  • To analyze the challenges in translating preclinical findings to clinical efficacy for anticancer therapeutics.

Main Methods:

  • Exploration of target identification, validation, and preclinical assessment of enzastaurin.
  • Review of clinical trial data from Phase I, II, and III, focusing on efficacy and safety.

Main Results:

  • Enzastaurin demonstrated encouraging preclinical results but exhibited poor efficacy in Phase II and III clinical trials, both as a single agent and in combination therapies.
  • Limited cytotoxicity was observed in Phase I trials, but overall clinical efficacy was insufficient for approval.

Conclusions:

  • The failure of enzastaurin highlights significant challenges in anticancer drug development, including poor preclinical-to-clinical translation, inadequate endpoint analysis, and insufficient patient stratification.
  • Issues such as limited biomarker analysis and suboptimal Phase I trial standards contributed to the lack of approval for enzastaurin as an anticancer therapeutic.